Blood Adv
Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
Akhtar OS, Oloyede T, Brazauskas R, et al
In this retrospective study, the authors describe the outcomes of older and frail patients receiving idecabtagene vicleucel using data from the Center for International Blood & Marrow Transplant Research. This large data set suggests that older adults, including frail patients, treated with idecabtagene vicleucel experience efficacy that is comparable to that observed in younger patients.
Previous Article
- • 3-Year Follow-Up From the Randomized, Phase 3 TRANSFORM Study
- • Final Results of the Phase 2 PILOT Study in Relapsed/Refractory Large B-Cell Lymphoma
- • Case Series: Lisocabtagene Maraleucel for Richter’s Transformation
- • Real-World Analysis of Lisocabtagene Maraleucel for Relapsed/Refractory Large B-cell Lymphoma
- • Implementation of a Lisocabtagene Maraleucel Outpatient Monitoring Program
- • Lisocabtagene Maraleucel Versus Second-Line Chemotherapy Regimens in the Real World
- • Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
- • Idecabtagene Vicleucel in Patients With Relapsed/Refractory Multiple Myeloma
- • Outcomes of Older Adults and Frail Patients Treated With Idecabtagene Vicleucel
- • Idecabtagene Vicleucel for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
- • KarMMa-3 Analyses: Idecabtagene Vicleucel in Triple Class-Exposed RRMM
- • Real-World Experience: Idecabtagene Vicleucel in Older Patients With Multiple Myeloma
